消炎药
医学
呕吐
中止
耐受性
止吐药
恶心
昂丹司琼
单中心
化疗引起恶心呕吐
麻醉
养生
粘膜炎
化疗
肿瘤科
内科学
不利影响
作者
Srivarshini Kanukollu,Krisoula Spatz,Jessica A. Lavery,Julia L. Glade Bender,Audrey Mauguen,Sherry Mathew
摘要
Abstract NK‐1 receptor antagonists (NK1‐RA) are key agents for chemotherapy‐induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy. Current pediatric practice guidelines recommend the use of intravenous fosaprepitant or oral aprepitant. However, there are reports of hypersensitivity reactions with fosaprepitant due to polysorbate 80. Intravenous aprepitant does not contain polysorbate 80, but its use in pediatric patients has not been described. In this retrospective, single‐center study, 106 pediatric patients received either fosaprepitant or intravenous aprepitant as part of their antiemetic regimen. Intravenous aprepitant was well tolerated and did not lead to any instances of hypersensitivity reactions requiring discontinuation.
科研通智能强力驱动
Strongly Powered by AbleSci AI